Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU.
Twenty-four patients with advanced metastatic colorectal cancer with measurable sites of disease were treated with a combination of 5-FU, methyl-CCNU, ICRF-159, and triazinate. Only two had objective regression of disease. Two patients died of complications from drug-induced myelosuppression. Toxic effects were moderate in the remaining patients. Attempts to escalate doses were limited by myelosuppression. The regimen used has no advantage over 5-FU alone. It is unlikely that triazinate and ICRF-159 will add substantially to the efficacy of chemotherapy for colorectal cancer.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D012673:Semustine / Q000009:adverse effects / Q000627:therapeutic use*; D014227:Triazines
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D010879:Piperazines; D014227:Triazines; D012673:Semustine; D011929:Razoxane; C012071:triazinate; D005472:Fluorouracil